Anavex Life Sciences Corp.: Research Report Reveals Cardioprotective Action Of Sigma-1 Receptor Agonists
Published: Mar 04, 2014
NEW YORK, March 4, 2014 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (OTCQB:AVXL) is encouraged by the findings of a research report published in the current issue of peer-reviewed scientific journal Life Sciences. Among its conclusions, the report reveals that sigma-1 receptor (S1R) agonists play an important role in the prevention, delay or reduction of heart disease. These findings correlate with the positive electrocardiogram (EKG) parameters in the successfully completed human clinical Phase 1 safety trial of ANAVEX 2-73, an orally available S1R agonist drug candidate developed to treat Alzheimer's through potential disease modification. ANAVEX 2-73 has also shown highly encouraging synergy with donepezil, the world's best-selling Alzheimer's drug, and a Phase 1b/2a clinical trial of this combination, ANAVEX PLUS, is planned for the first half of 2014.
Help employers find you! Check out all the jobs and post your resume.